Item 8.01 Other Events.

On January 3, 2021, Selecta Biosciences, Inc. (the "Company") entered into a Collaboration and License Agreement (the "Agreement") with Ginkgo Bioworks, Inc., a Delaware corporation, ("Ginkgo"). Under the Agreement, the Company will engage with Ginkgo to develop AAV capsids designed to enhance transduction efficiency and transgene expression. In return, Ginkgo is eligible to earn both upfront research and development fees and milestone payments, including certain milestone payments in the form of Selecta common stock, clinical and commercial milestone payments of up to $207M in cash, as well as downstream value in the form of royalties on sales.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses